Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlmasi, E.-
dc.contributor.authorStafford, R.-
dc.contributor.authorKravitz, R.-
dc.contributor.authorMansfield, P.-
dc.identifier.citationPLoS Medicine, 2006; 3(3):284-288-
dc.description.abstractOnly two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.-
dc.description.statementofresponsibilityElizabeth A. Almasi, Randall S. Stafford, Richard L. Kravitz, Peter R. Mansfield-
dc.publisherPublic Library of Science-
dc.rightsCopyright: © 2006 Almasi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.-
dc.subjectPatient Compliance-
dc.subjectPublic Health-
dc.subjectPlacebo Effect-
dc.subjectDrug Industry-
dc.subjectUnited States-
dc.subjectNew Zealand-
dc.subjectCommunity Participation-
dc.titleWhat are the public health effects of direct-to-consumer drug advertising?-
dc.typeJournal article-
Appears in Collections:Aurora harvest 6
General Practice publications

Files in This Item:
File Description SizeFormat 
hdl_22744.pdfPublished version160.16 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.